-
Your prediction
Intercept Pharmaceuticals Stock
Pros and Cons of Intercept Pharmaceuticals in the next few years
Pros
Cons
Performance of Intercept Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Intercept Pharmaceuticals | - | - | - | - | - | - | - |
| Ardelyx Inc. | 0.060% | -5.210% | -13.459% | 49.277% | 10.796% | -11.669% | - |
| Salarius Pharmaceuticals Inc. | 5.880% | -0.971% | -34.720% | -69.778% | -26.486% | -98.400% | -99.995% |
| Evolus Inc | -2.630% | -8.197% | -12.500% | 43.590% | 19.786% | 18.519% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Intercept Pharmaceuticals, a company within the Biotechnology & Medical Research industry, has seen mixed financial performance in recent years. Analyzing the financial statements provides an insight into the company's position by assessing its strengths and weaknesses. Before diving into a detailed analysis, our general impression of the company's financials is that while there are some positive signs in revenue and gross profit, there are also concerns about increasing debt and consistently negative net income.
*Pros: *
Increasing Revenue: Over the years, Intercept's total revenues have been growing, with an increase from $312.69 million in 2020 to $363.47 million in 2021, and further to $285.71 million in 2022. A steady growth in revenues signifies market acceptance and demand for the company's products.
